As of 23 July 2026, the Icelandic Customs Service launched a targeted assessment concerning the import of illegal peptides discovered during a major seizure of substances across the country. The initiative forms part of broader efforts to enforce customs regulations on unconventional chemical imports that may bypass standard tax and health controls. The assessment also examines whether the imported peptides qualify as medicinal products under Icelandic law, which would trigger specific registration and taxation requirements. Additionally, the Customs Service is coordinating with the Icelandic Medicines Agency and the Tax Office to share data and ensure consistent application of VAT and excise duties where applicable. The findings will be published in a detailed report to be submitted to the Ministry of Finance and Economic Affairs by the end of the fiscal year, outlining recommended adjustments to import classification codes and related tax codes.
Key Takeaways
- Scope: The review covers all shipments of unregulated peptides intercepted between January and June 2026, focusing on potential tax evasion, health‑related risks, and compliance with Icelandic medicinal product regulations.
- Customs Action: Enhanced verification procedures have been instituted, requiring electronic proof of origin, stricter deadline compliance for customs inspections, and closer collaboration with the Icelandic Medicines Agency to monitor potential misuse.
- Tax Impact: Any fraudulent classification of these peptides may result in additional import duties, penalties, and potential criminal prosecution under tax evasion statutes, as well as possible VAT liabilities and registration obligations for pharmaceutical imports.
Source: Read Original Announcement